- Home
- RAC vs XFOR Comparison
RAC vs XFOR Comparison
Compare RAC & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAC
- XFOR
- Stock Information
- Founded
- RAC 2024
- XFOR 2014
- Country
- RAC United States
- XFOR United States
- Employees
- RAC N/A
- XFOR N/A
- Industry
- RAC
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RAC
- XFOR Health Care
- Exchange
- RAC Nasdaq
- XFOR Nasdaq
- Market Cap
- RAC 301.5M
- XFOR 320.0M
- IPO Year
- RAC 2025
- XFOR N/A
- Fundamental
- Price
- RAC $10.39
- XFOR $3.55
- Analyst Decision
- RAC
- XFOR Strong Buy
- Analyst Count
- RAC 0
- XFOR 3
- Target Price
- RAC N/A
- XFOR $34.17
- AVG Volume (30 Days)
- RAC 18.4K
- XFOR 1.7M
- Earning Date
- RAC 01-01-0001
- XFOR 11-05-2025
- Dividend Yield
- RAC N/A
- XFOR N/A
- EPS Growth
- RAC N/A
- XFOR N/A
- EPS
- RAC N/A
- XFOR N/A
- Revenue
- RAC N/A
- XFOR $33,979,000.00
- Revenue This Year
- RAC N/A
- XFOR $1,307.51
- Revenue Next Year
- RAC N/A
- XFOR N/A
- P/E Ratio
- RAC N/A
- XFOR N/A
- Revenue Growth
- RAC N/A
- XFOR 2925.74
- 52 Week Low
- RAC $9.87
- XFOR $1.35
- 52 Week High
- RAC $10.42
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- RAC N/A
- XFOR 50.96
- Support Level
- RAC N/A
- XFOR $2.96
- Resistance Level
- RAC N/A
- XFOR $4.15
- Average True Range (ATR)
- RAC 0.00
- XFOR 0.29
- MACD
- RAC 0.00
- XFOR 0.05
- Stochastic Oscillator
- RAC 0.00
- XFOR 39.63
About RAC Rithm Acquisition Corp. Class A Ordinary Shares
Rithm Acquisition Corp is a blank check company.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.